20.55
前日終値:
$19.65
開ける:
$20.04
24時間の取引高:
357.66K
Relative Volume:
0.87
時価総額:
$1.06B
収益:
-
当期純損益:
$-85.21M
株価収益率:
-10.87
EPS:
-1.89
ネットキャッシュフロー:
$-68.53M
1週間 パフォーマンス:
-4.53%
1か月 パフォーマンス:
+7.24%
6か月 パフォーマンス:
-14.12%
1年 パフォーマンス:
-5.41%
Enliven Therapeutics Inc Stock (ELVN) Company Profile
ELVN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ELVN
Enliven Therapeutics Inc
|
20.53 | 1.06B | 0 | -85.21M | -68.53M | -1.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
454.76 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
548.16 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
549.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.46 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-16 | 開始されました | Goldman | Buy |
2024-12-13 | 開始されました | BTIG Research | Buy |
2024-09-09 | 開始されました | H.C. Wainwright | Buy |
2024-06-11 | 開始されました | Robert W. Baird | Outperform |
2024-04-09 | 開始されました | Mizuho | Buy |
2023-03-29 | 開始されました | Jefferies | Buy |
すべてを表示
Enliven Therapeutics Inc (ELVN) 最新ニュース
Enliven Therapeutics CEO Kintz sells $277k in shares By Investing.com - Investing.com India
Enliven grosses $230M from stock sale - BizWest
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Eastern Progress
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data - MSN
Enliven Raises $230m To Fund Scemblix Leukemia Challenger - insights.citeline.com
Enliven Therapeutics (NASDAQ:ELVN) Given New $52.00 Price Target at Robert W. Baird - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up on Analyst Upgrade - Defense World
10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey
Enliven Therapeutics Closes Public Offering - MarketScreener
Biotech Enliven Therapeutics Secures Massive $230M Funding Through Oversubscribed Public Offering - Stock Titan
Form 424B5 Enliven Therapeutics, - StreetInsider
Enliven (ELVN) Gains Buy Rating from Goldman Sachs with $37 Price Target | ELVN Stock News - GuruFocus
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down – Should You Sell? - Defense World
Enliven (ELVN) Initiates $200M Public Stock Offering | ELVN Stoc - GuruFocus
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The Malaysian Reserve
Enliven Therapeutics prices $200 million public offering By Investing.com - Investing.com South Africa
Enliven Therapeutics Inc (ELVN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Enliven to sell $200M in stock after positive drug trial - BizWest
Enliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded Warrants - Nasdaq
Enliven Therapeutics prices $200 million public offering - Investing.com
Biotech Breakthrough: Enliven Therapeutics Secures Massive $200M Funding Backed by Goldman Sachs - Stock Titan
Enliven Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com
Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares - Nasdaq
Enliven Therapeutics Launches $200 Million Securities Offering - marketscreener.com
Enliven Therapeutics Announces Positive Phase 1 Trial Results - TipRanks
Enliven Therapeutics announces $200 million public offering - Investing.com
SEC Form 424B5 filed by Enliven Therapeutics Inc. - Quantisnow
Biotech Enliven Therapeutics Unveils Massive $200M Stock Offering with Pre-Funded Warrants Option - Stock Titan
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PR Newswire
California State Teachers Retirement System Buys 1,940 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Two Sigma Investments LP Has $329,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Bank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4% After Insider Selling - Defense World
Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
ELVN Stock Price and Chart — NASDAQ:ELVN - TradingView
Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings? - Defense World
(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
BNP Paribas Financial Markets Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN Q2 Earnings? - Defense World
Enliven Therapeutics (ELVN) Gets a Buy from Mizuho Securities - The Globe and Mail
Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating - marketscreener.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Increased by Deutsche Bank AG - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.25 Consensus PT from Analysts - Defense World
Enliven Therapeutics to Present at Upcoming Investor Conferences - Nasdaq
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics chief scientific officer sells $81,533 in stock - Investing.com Australia
Enliven Therapeutics chief scientific officer sells $81,533 in stock By Investing.com - Investing.com India
Enliven Therapeutics Inc (ELVN) 財務データ
収益
当期純利益
現金流量
EPS
Enliven Therapeutics Inc (ELVN) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Jun 27 '25 |
Sale |
20.91 |
3,250 |
67,956 |
23,000 |
大文字化:
|
ボリューム (24 時間):